트라이콤바이오

비상장계속사업자

TRICOM BIO CO., LTD

민병관

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

트라이콤바이오

Business Reg. No. 2158611777 · CEO 민병관

I.Investment Overview

Target트라이콤바이오 (2158611777)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명트라이콤바이오
영문명TRICOM BIO CO., LTD
대표자민병관
사업자등록번호2158611777
법인등록번호1101112285173
설립일2001.07.26
종업원수16명

V.Workforce

16

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW283.72021357.62022255.12023227.52024214.22025
영업이익100M KRW34.5202119.920220.620236.420245.62025
순이익100M KRW25.7202113.420222.320237.420247.62025
Item20252024202320222021
자산총계159.5억원164.8억원153.8억원160.7억원135.2억원
부채총계37.1억원45억원36.4억원40.2억원23.1억원
자본총계122.4억원119.8억원117.4억원120.5억원112.1억원
매출액214.2억원227.5억원255.1억원357.6억원283.7억원
영업이익5.6억원6.4억원5,582만원19.9억원34.5억원
순이익7.6억원7.4억원2.3억원13.4억원25.7억원

VII.Financial Ratios

FY2025 basis

2.6%

영업이익률

3.55%

순이익률

4.77%

ROA

6.21%

ROE

30.3%

부채비율

76.75%

자기자본비율

VIII.R&D Activity

Fields 농림수산식품 > 식품영양과학 · 농림수산식품 > 수산자원/어장환경

Keywords 비파엽, 건강기능식품, 전임상

YearProjectsPapersPatents
2025010
2024100
2023100

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

트라이콤바이오 투심보고서 | Alpha Lenz